Gilead(US:GILD) ZACKS·2026-02-10 23:11分组1 - Gilead Sciences reported quarterly earnings of $1.86 per share, exceeding the Zacks Consensus Estimate of $1.83 per share, but down from $1.90 per share a year ago, representing an earnings surprise of +1.91% [1] - The company achieved revenues of $7.93 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 4.63% and up from $7.57 billion year-over-year [2] - Gilead shares have increased approximately 23.6% since the beginning of the year, significantly outperforming the S&P 500's gain of 1.7% [3] 分组2 - The earnings outlook for Gilead is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the next quarter is $1.90 on revenues of $6.84 billion, and for the current fiscal year, it is $8.61 on revenues of $30.04 billion [7] - The Medical - Biomedical and Genetics industry, to which Gilead belongs, is currently ranked in the top 36% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]